{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T12:25:11Z","timestamp":1786969511080,"version":"build-2736575974"},"reference-count":223,"publisher":"Compuscript, Ltd.","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:p>Prostate cancer (PrCa) is the most prevalent urogenital cancer affecting men. PrCa is marked by uncontrolled cellular growth that leads to abnormal enlargement of the prostate gland. The metastatic spread of PrCa is the primary cause of mortality, causing cancer cell dissemination to distant sites, such as bones, the pelvis, and various visceral organs. Key contributors to PrCa progression include genetic mutations, elevated androgen receptor expression, gene amplification, and the rise of androgen receptor splice variants. Although androgen deprivation therapy remains the mainstay for early-stage PrCa treatment, efficacy is temporary because many cases advance to castration-resistant PrCa (CRPC), presenting a significant therapeutic hurdle. This review explores key biomarkers for PrCa and the latest therapeutic strategies for CRPC with a particular focus on the innovative proteolysis-targeting chimera (PROTAC) technology. This approach offers a novel means of degrading target proteins and we discuss how PROTAC holds potential as effective strategies to combat resistance mechanisms in CRPC.<\/jats:p>","DOI":"10.15212\/amm-2024-0075","type":"journal-article","created":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T04:10:24Z","timestamp":1738210224000},"source":"Crossref","is-referenced-by-count":4,"title":["PROTAC technology for prostate cancer treatment"],"prefix":"10.15212","volume":"4","author":[{"given":"Zhen","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dingpeng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Inuzuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyi","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"5858","published-online":{"date-parts":[[2025]]},"reference":[{"key":"r1","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/nrc801","article-title":"A History of Prostate Cancer Treatment","volume":"2","author":"SR Denmeade","year":"2002","journal-title":"Nature Reviews. Cancer"},{"key":"r2","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1186\/s12935-022-02685-w","article-title":"The Role of Ferroptosis in Esophageal Cancer","volume":"22","author":"Z Wang","year":"2022","journal-title":"Cancer Cell International"},{"key":"r3","first-page":"7","article-title":"Cancer Statistics, 2022","volume":"72","author":"RL Siegel","year":"2022","journal-title":"CA: A Cancer Journal for Clinicians"},{"key":"r4","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41391-017-0023-8","article-title":"The Molecular Biology of Prostate Cancer: Current Understanding and Clinical Implications","volume":"21","author":"J Gandhi","year":"2018","journal-title":"Prostate Cancer and Prostatic Diseases"},{"key":"r5","doi-asserted-by":"crossref","first-page":"7645","DOI":"10.7150\/thno.44556","article-title":"Molecular Analysis of Circulating Tumor Cells of Metastatic Castration-resistant Prostate Cancer Patients receiving (177)Lu-PSMA-617 Radioligand Therapy","volume":"10","author":"K Kessel","year":"2020","journal-title":"Theranostics"},{"key":"r6","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.canlet.2021.07.013","article-title":"Androgen Receptor Splice Variant 7 Functions Independently of the Full Length Receptor in Prostate Cancer Cells","volume":"519","author":"J Liang","year":"2021","journal-title":"Cancer Letters"},{"key":"r7","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/nrd.2016.120","article-title":"Drug Discovery in Advanced Prostate Cancer: Translating Biology into Therapy","volume":"15","author":"TA Yap","year":"2016","journal-title":"Nature Reviews. Drug Discovery"},{"key":"r8","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","article-title":"PROTAC Targeted Protein Degraders: the Past is Prologue","volume":"21","author":"M Bekes","year":"2022","journal-title":"Nature Reviews Drug Discovery"},{"key":"r9","doi-asserted-by":"crossref","first-page":"22986","DOI":"10.1074\/jbc.M002807200","article-title":"FXXLF and WXXLF Sequences Mediate the NH2-terminal Interaction with the Ligand Binding Domain of the Androgen Receptor","volume":"275","author":"B He","year":"2000","journal-title":"The Journal of Biological Chemistry"},{"key":"r10","first-page":"4562","article-title":"Filamin-A Fragment Localizes to the Nucleus to Regulate Androgen Receptor and Coactivator Functions","volume":"100","author":"CJ Loy","year":"2003","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"r11","doi-asserted-by":"crossref","first-page":"37219","DOI":"10.1074\/jbc.274.52.37219","article-title":"Activation Function 2 in the Human Androgen Receptor Ligand Binding Domain Mediates Interdomain Communication with the NH(2)-Terminal Domain","volume":"274","author":"B He","year":"1999","journal-title":"The Journal of Biological Chemistry"},{"key":"r12","doi-asserted-by":"crossref","first-page":"7422","DOI":"10.1021\/bi00147a029","article-title":"Hormone-induced Dissociation of the Androgen Receptor-heat-shock Protein Complex: Use of a New Monoclonal Antibody to Distinguish Transformed from Nontransformed Receptors","volume":"31","author":"J Veldscholte","year":"1992","journal-title":"Biochemistry"},{"key":"r13","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1210\/mend.14.10.0541","article-title":"Androgen Receptor Nuclear Translocation is Facilitated by the f-actin Cross-linking Protein Filamin","volume":"14","author":"DM Ozanne","year":"2000","journal-title":"Molecular Endocrinology"},{"key":"r14","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S0003-9861(02)00680-X","article-title":"C-Terminal Hsp-interacting Protein Slows Androgen Receptor Synthesis and Reduces Its Rate of Degradation","volume":"410","author":"CP Cardozo","year":"2003","journal-title":"Archives of Biochemistry and Biophysics"},{"key":"r15","doi-asserted-by":"crossref","first-page":"7189","DOI":"10.1128\/MCB.23.20.7189-7197.2003","article-title":"The Cochaperone Bag-1L Enhances Androgen Receptor Action via Interaction with the NH2-terminal Region of the Receptor","volume":"23","author":"L Shatkina","year":"2003","journal-title":"Molecular and Cellular Biology"},{"key":"r16","doi-asserted-by":"crossref","first-page":"5052","DOI":"10.1074\/jbc.M206374200","article-title":"Regulation of Androgen Receptor Activity by the Nuclear Receptor Corepressor SMRT","volume":"278","author":"G Liao","year":"2003","journal-title":"The Journal of Biological Chemistry"},{"key":"r17","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1242\/jcs.022103","article-title":"Structural Basis for the Nuclear Import of the Human Androgen Receptor","volume":"121","author":"ML Cutress","year":"2008","journal-title":"Journal of Cell Science"},{"key":"r18","doi-asserted-by":"crossref","first-page":"25631","DOI":"10.1074\/jbc.M202809200","article-title":"Dependence of Selective Gene Activation on the Androgen Receptor NH2- and COOH-terminal Interaction","volume":"277","author":"B He","year":"2002","journal-title":"The Journal of Biological Chemistry"},{"key":"r19","doi-asserted-by":"crossref","first-page":"14724","DOI":"10.1073\/pnas.96.26.14724","article-title":"Convergence of Two Repressors Through Heterodimer Formation of Androgen Receptor and Testicular Orphan Receptor-4: A Unique Signaling Pathway in the Steroid Receptor Superfamily","volume":"96","author":"YF Lee","year":"1999","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"r20","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1158\/1078-0432.CCR-0746-3","article-title":"Androgen Receptor Coregulators in Prostate Cancer: Mechanisms and Clinical Implications","volume":"10","author":"M Rahman","year":"2004","journal-title":"Clinical Cancer Research: An Official Journal of the American Association for Cancer Research"},{"key":"r21","doi-asserted-by":"crossref","first-page":"9802","DOI":"10.1073\/pnas.0408819102","article-title":"The Structural Basis of Androgen Receptor Activation: Intramolecular and Intermolecular Amino-carboxy Interactions","volume":"102","author":"F Schaufele","year":"2005","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"r22","doi-asserted-by":"crossref","first-page":"13115","DOI":"10.1016\/S0021-9258(17)36806-0","article-title":"A Ligand-dependent Bipartite Nuclear Targeting Signal in the Human Androgen Receptor. Requirement for the DNA-binding Domain and Modulation by NH2-terminal and Carboxyl-terminal Sequences","volume":"269","author":"ZX Zhou","year":"1994","journal-title":"The Journal of Biological Chemistry"},{"key":"r23","doi-asserted-by":"crossref","first-page":"3719","DOI":"10.1038\/sj.onc.1209408","article-title":"Regulator of G-protein Signaling 2 (RGS2) Inhibits Androgen-independent Activation of Androgen Receptor in Prostate Cancer Cells","volume":"25","author":"X Cao","year":"2006","journal-title":"Oncogene"},{"key":"r24","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1042\/bj20020585","article-title":"Androgen Receptor Expression is Regulated by the Phosphoinositide 3-kinase\/Akt Pathway in Normal and Tumoral Epithelial Cells","volume":"366","author":"M Manin","year":"2002","journal-title":"The Biochemical Journal"},{"key":"r25","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1038\/35096067","article-title":"PKB\/AKT: Functional Insights from Genetic Models","volume":"2","author":"MP Scheid","year":"2001","journal-title":"Nature Reviews. Molecular Cell Biology"},{"key":"r26","doi-asserted-by":"crossref","first-page":"5458","DOI":"10.1073\/pnas.96.10.5458","article-title":"From HER2\/Neu Signal Cascade to Androgen Receptor and Its Coactivators: A Novel Pathway by Induction of Androgen Target Genes Through MAP Kinase in Prostate Cancer Cells","volume":"96","author":"S Yeh","year":"1999","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"r27","doi-asserted-by":"crossref","first-page":"29304","DOI":"10.1074\/jbc.M204131200","article-title":"Androgen Receptor Phosphorylation. Regulation and Identification of the Phosphorylation Sites","volume":"277","author":"D Gioeli","year":"2002","journal-title":"The Journal of Biological Chemistry"},{"key":"r28","doi-asserted-by":"crossref","first-page":"3850","DOI":"10.1021\/bi9724422","article-title":"Forskolin-induced Dephosphorylation of the Androgen Receptor Impairs Ligand Binding","volume":"37","author":"LJ Blok","year":"1998","journal-title":"Biochemistry"},{"key":"r29","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0898-6568(02)00115-8","article-title":"Nuclear Receptors: Integration of Multiple Signalling Pathways Through Phosphorylation","volume":"15","author":"C Rochette-Egly","year":"2003","journal-title":"Cellular Signalling"},{"key":"r30","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1083\/jcb.200609178","article-title":"Compartmentalization of Androgen Receptor Protein-protein Interactions in Living Cells","volume":"177","author":"ME van Royen","year":"2007","journal-title":"The Journal of Cell Biology"},{"key":"r31","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1210\/edrv.23.2.0460","article-title":"Androgen Receptor (AR) Coregulators: An Overview","volume":"23","author":"CA Heinlein","year":"2002","journal-title":"Endocrine Reviews"},{"key":"r32","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1677\/erc.0.0110117","article-title":"Mechanisms of Androgen Receptor Signalling via Steroid Receptor Coactivator-1 in Prostate","volume":"11","author":"SM Powell","year":"2004","journal-title":"Endocrine-Related Cancer"},{"key":"r33","doi-asserted-by":"crossref","first-page":"4187","DOI":"10.1242\/jcs.02546","article-title":"Antiandrogens Prevent Stable DNA-binding of the Androgen Receptor","volume":"118","author":"P Farla","year":"2005","journal-title":"Journal of Cell Science"},{"key":"r34","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1128\/MCB.01297-06","article-title":"Ligand-specific Dynamics of the Androgen Receptor at Its Response Element in Living Cells","volume":"27","author":"TI Klokk","year":"2007","journal-title":"Molecular and Cellular Biology"},{"key":"r35","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1093\/nar\/gki141","article-title":"Regulation of Androgen Receptor and Histone Deacetylase 1 by Mdm2-mediated Ubiquitylation","volume":"33","author":"L Gaughan","year":"2005","journal-title":"Nucleic Acids Research"},{"key":"r36","doi-asserted-by":"crossref","first-page":"4514","DOI":"10.1158\/0008-5472.CAN-06-1701","article-title":"The Hinge Region Regulates DNA Binding, Nuclear Translocation, and Transactivation of the Androgen Receptor","volume":"67","author":"A Haelens","year":"2007","journal-title":"Cancer Research"},{"key":"r37","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1210\/jc.2003-030261","article-title":"Endocrine Mechanisms of Disease: Expression and Degradation of Androgen Receptor: Mechanism and Clinical Implication","volume":"88","author":"DK Lee","year":"2003","journal-title":"The Journal of Clinical Endocrinology and Metabolism"},{"key":"r38","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1006\/bbrc.2000.3424","article-title":"Inhibiting Proteasomes in Human HepG2 and LNCaP Cells Increases Endogenous Androgen Receptor Levels","volume":"276","author":"L Sheflin","year":"2000","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"r39","first-page":"81","article-title":"Prostate-specific Membrane Antigen Expression in Normal and Malignant Human Tissues","volume":"3","author":"DA Silver","year":"1997","journal-title":"Clinical Cancer Research: An Official Journal of the American Association for Cancer Research"},{"key":"r40","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/1078-1439(95)00002-Y","article-title":"Expression of Prostate-specific Membrane Antigen in Normal, Benign, and Malignant Prostate Tissues","volume":"1","author":"GL Wright","year":"1995","journal-title":"Urologic Oncology"},{"key":"r41","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.2174\/092986712799462649","article-title":"Glutamate in CNS Neurodegeneration and Cognition and Its Regulation by GCPII Inhibition","volume":"19","author":"KA Rahn","year":"2012","journal-title":"Current Medicinal Chemistry"},{"key":"r42","doi-asserted-by":"crossref","first-page":"20101","DOI":"10.1073\/pnas.1209934109","article-title":"Inhibition of Glutamate Carboxypeptidase II (GCPII) Activity as a Treatment for Cognitive Impairment in Multiple Sclerosis","volume":"109","author":"KA Rahn","year":"2012","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"r43","doi-asserted-by":"crossref","first-page":"5981","DOI":"10.1073\/pnas.0502101102","article-title":"Crystal Structure of Prostate-specific Membrane Antigen, A Tumor Marker and Peptidase","volume":"102","author":"MI Davis","year":"2005","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"r44","doi-asserted-by":"crossref","first-page":"12590","DOI":"10.1073\/pnas.1735443100","article-title":"The Homodimer of Prostate-specific Membrane Antigen is a Functional Target for Cancer Therapy","volume":"100","author":"N Schulke","year":"2003","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"r45","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S0167-4838(97)00008-3","article-title":"Structure of Membrane Glutamate Carboxypeptidase","volume":"1339","author":"ND Rawlings","year":"1997","journal-title":"Biochimica et Biophysica Acta"},{"key":"r46","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/0002-9343(70)90006-9","article-title":"The Absorption and Malabsorption of Folic Acid and Its Polyglutamates","volume":"48","author":"LH Bernstein","year":"1970","journal-title":"The American Journal of Medicine"},{"key":"r47","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1146\/annurev-nutr-072610-145133","article-title":"Mechanisms of Membrane Transport of Folates into Cells and Across Epithelia","volume":"31","author":"R Zhao","year":"2011","journal-title":"Annual Review of Nutrition"},{"key":"r48","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1093\/jnci\/djp019","article-title":"Folic Acid and Risk of Prostate Cancer: Results from a Randomized Clinical Trial","volume":"101","author":"JC Figueiredo","year":"2009","journal-title":"Journal of the National Cancer Institute"},{"key":"r49","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/s41568-019-0187-8","article-title":"Methionine Metabolism in Health and Cancer: A Nexus of Diet and Precision Medicine","volume":"19","author":"SM Sanderson","year":"2019","journal-title":"Nature Reviews. Cancer"},{"key":"r50","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1002\/pros.20361","article-title":"Prostate Specific Membrane Antigen (PSMA) Expression Gives Prostate Cancer Cells a Growth Advantage in a Physiologically Relevant Folate Environment In Vitro","volume":"66","author":"V Yao","year":"2006","journal-title":"The Prostate"},{"key":"r51","doi-asserted-by":"crossref","DOI":"10.3390\/ijms17081208","article-title":"One-Carbon Metabolism in Prostate Cancer: The Role of Androgen Signaling","volume":"17","author":"JM Corbin","year":"2016","journal-title":"International Journal of Molecular Sciences"},{"key":"r52","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1073\/pnas.1808834116","article-title":"Inhibition of De Novo Lipogenesis Targets Androgen Receptor Signaling in Castration-resistant Prostate Cancer","volume":"116","author":"G Zadra","year":"2019","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"r53","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41585-024-00900-z","article-title":"Biological Determinants of PSMA Expression, Regulation and Heterogeneity in Prostate Cancer","volume":"22","author":"MK Bakht","year":"2024","journal-title":"Nature Reviews Urology"},{"key":"r54","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1046\/j.1471-4159.2000.0750443.x","article-title":"N-Acetylaspartylglutamate: The Most Abundant Peptide Neurotransmitter in the Mammalian Central Nervous System","volume":"75","author":"JH Neale","year":"2000","journal-title":"Journal of Neurochemistry"},{"key":"r55","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23031268","article-title":"N-Acetyl-Aspartyl-Glutamate in Brain Health and Disease","volume":"23","author":"C Morland","year":"2022","journal-title":"International Journal of Molecular Sciences"},{"key":"r56","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1084\/jem.20171052","article-title":"Prostate-specific Membrane Antigen Cleavage of Vitamin B9 Stimulates Oncogenic Signaling Through Metabotropic Glutamate Receptors","volume":"215","author":"C Kaittanis","year":"2018","journal-title":"The Journal of Experimental Medicine"},{"key":"r57","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1084\/jem.20172050","article-title":"PSMA Brings New Flavors to PI3K Signaling: A Role for Glutamate in Prostate Cancer","volume":"215","author":"L Palamiuc","year":"2018","journal-title":"The Journal of Experimental Medicine"},{"key":"r58","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2025710119","article-title":"Identification of Alternative Protein Targets of Glutamate-ureido-lysine Associated with PSMA Tracer Uptake in Prostate Cancer Cells","volume":"119","author":"MK Bakht","year":"2022","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"r59","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1007\/s00259-023-06388-w","article-title":"A Look into the Future: The Role of PSMA Beyond Prostate Cancer","volume":"51","author":"S Pellegrino","year":"2023","journal-title":"European Journal of Nuclear Medicine and Molecular Imaging"},{"key":"r60","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1002\/ijc.27338","article-title":"MTHFR Polymorphisms, Folate Intake and Carcinogen DNA Adducts in the Lung","volume":"131","author":"MS Lee","year":"2012","journal-title":"International Journal of Cancer"},{"key":"r61","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1002\/pros.21065","article-title":"Expression of Prostate-specific Membrane Antigen (PSMA), Increases Cell Folate Uptake and Proliferation and Suggests a Novel Role for PSMA in the Uptake of the Non-polyglutamated Folate, Folic Acid","volume":"70","author":"V Yao","year":"2010","journal-title":"The Prostate"},{"key":"r62","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/nature13229","article-title":"Therapeutic Targeting of BET Bromodomain Proteins in Castration-resistant Prostate Cancer","volume":"510","author":"IA Asangani","year":"2014","journal-title":"Nature"},{"key":"r63","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.celrep.2014.06.016","article-title":"Bromodomain Protein BRD4 is Required for Estrogen Receptor-dependent Enhancer Activation and Gene Transcription","volume":"8","author":"S Nagarajan","year":"2014","journal-title":"Cell Reports"},{"key":"r64","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.molcel.2014.05.016","article-title":"The Mechanisms Behind the Therapeutic Activity of BET Bromodomain Inhibition","volume":"54","author":"J Shi","year":"2014","journal-title":"Molecular Cell"},{"key":"r65","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.cell.2011.08.017","article-title":"BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc","volume":"146","author":"JE Delmore","year":"2011","journal-title":"Cell"},{"key":"r66","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.18632\/oncotarget.1572","article-title":"Inhibition of BET Bromodomain Proteins as a Therapeutic Approach in Prostate Cancer","volume":"4","author":"A Wyce","year":"2013","journal-title":"Oncotarget"},{"key":"r67","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1016\/j.celrep.2017.05.049","article-title":"Androgen Receptor Deregulation Drives Bromodomain-Mediated Chromatin Alterations in Prostate Cancer","volume":"19","author":"A Urbanucci","year":"2017","journal-title":"Cell Reports"},{"key":"r68","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.urolonc.2013.09.017","article-title":"Prostate Cancer Biomarkers: An Update","volume":"32","author":"J Romero Otero","year":"2014","journal-title":"Urologic Oncology"},{"key":"r69","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1373\/clinchem.2007.101204","article-title":"Testing New PSA Subforms to Enhance the Accuracy of Predicting Cancer Risk and Disease Outcome in Prostate Cancer","volume":"54","author":"H Lilja","year":"2008","journal-title":"Clinical Chemistry"},{"key":"r70","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/nrc2351","article-title":"Prostate-specific Antigen and Prostate Cancer: Prediction, Detection and Monitoring","volume":"8","author":"H Lilja","year":"2008","journal-title":"Nature Reviews. Cancer"},{"key":"r71","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1177\/1756287213495915","article-title":"Biomarkers in Prostate Cancer Surveillance and Screening: Past, Present, and Future","volume":"5","author":"KC Cary","year":"2013","journal-title":"Therapeutic Advances in Urology"},{"key":"r72","doi-asserted-by":"crossref","DOI":"10.1177\/17562872221103988","article-title":"Biomarkers for Prostate Cancer Detection and Risk Stratification","volume":"14","author":"MW Farha","year":"2022","journal-title":"Therapeutic Advances in Urology"},{"key":"r73","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1158\/1055-9965.EPI-10-0007","article-title":"A Prospective Multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: Improving Prostate Cancer Detection and Correlating with Cancer Aggressiveness","volume":"19","author":"LJ Sokoll","year":"2010","journal-title":"Cancer Epidemiology, Biomarkers & Prevention: A Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology"},{"key":"r74","first-page":"5975","article-title":"DD3: A New Prostate-specific Gene, Highly Overexpressed in Prostate Cancer","volume":"59","author":"MJ Bussemakers","year":"1999","journal-title":"Cancer Research"},{"key":"r75","first-page":"2695","article-title":"DD3(PCA3), A Very Sensitive and Specific Marker to Detect Prostate Tumors","volume":"62","author":"JB de Kok","year":"2002","journal-title":"Cancer Research"},{"key":"r76","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/B978-0-12-387688-1.00007-7","article-title":"Prostate Cancer as a Model System for Genetic Diversity in Tumors","volume":"112","author":"JA Squire","year":"2011","journal-title":"Advances in Cancer Research"},{"key":"r77","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.eururo.2011.08.003","article-title":"Contemporary Role of Prostate Cancer Antigen 3 in the Management of Prostate Cancer","volume":"60","author":"M Auprich","year":"2011","journal-title":"European Urology"},{"key":"r78","doi-asserted-by":"crossref","first-page":"4058","DOI":"10.1158\/1078-0432.CCR-12-3606","article-title":"Genomic Profiling Defines Subtypes of Prostate Cancer with the Potential for Therapeutic Stratification","volume":"19","author":"JR Schoenborn","year":"2013","journal-title":"Clinical Cancer Research: An Official Journal of the American Association for Cancer Research"},{"key":"r79","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1016\/j.juro.2012.07.023","article-title":"Diagnostic Performance of PCA3 to Detect Prostate Cancer in Men with Increased Prostate Specific Antigen: A Prospective Study of 1,962 Cases","volume":"188","author":"ED Crawford","year":"2012","journal-title":"The Journal of Urology"},{"key":"r80","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.urology.2009.03.046","article-title":"Urinary Prostate Cancer 3 Test: Toward the Age of Reason?","volume":"75","author":"V Vlaeminck-Guillem","year":"2010","journal-title":"Urology"},{"key":"r81","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1002\/cncr.10977","article-title":"Factors Affecting Recurrence Rates after Prostatectomy or Radiotherapy in Localized Prostate Carcinoma Patients with Biopsy Gleason Score 8 or Above","volume":"95","author":"PA Kupelian","year":"2002","journal-title":"Cancer"},{"key":"r82","doi-asserted-by":"crossref","DOI":"10.3390\/molecules27175730","article-title":"Prostate Cancer Review: Genetics, Diagnosis, Treatment Options, and Alternative Approaches","volume":"27","author":"M Sekhoacha","year":"2022","journal-title":"Molecules"},{"key":"r83","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1016\/S0140-6736(18)32486-3","article-title":"Radiotherapy to the Primary Tumour for Newly Diagnosed, Metastatic Prostate Cancer (STAMPEDE): A Randomised Controlled Phase 3 Trial","volume":"392","author":"CC Parker","year":"2018","journal-title":"Lancet"},{"key":"r84","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer","volume":"373","author":"CJ Sweeney","year":"2015","journal-title":"The New England Journal of Medicine"},{"key":"r85","doi-asserted-by":"crossref","first-page":"551","DOI":"10.21873\/anticanres.14807","article-title":"PARP Inhibitors in Prostate Cancer","volume":"41","author":"K Grewal","year":"2021","journal-title":"Anticancer Research"},{"key":"r86","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.mce.2017.06.007","article-title":"Bromodomain-containing Proteins in Prostate Cancer","volume":"462","author":"A Urbanucci","year":"2018","journal-title":"Molecular and Cellular Endocrinology"},{"key":"r87","first-page":"341","article-title":"Epigenetics in Prostate Cancer Treatment","volume":"5","author":"K Jones","year":"2021","journal-title":"Journal of Translational Genetics and Genomics"},{"key":"r88","article-title":"The Novel BET-CBP\/p300 Dual Inhibitor NEO2734 is Active in SPOP Mutant and Wild-type Prostate Cancer","volume":"11","author":"Y Yan","year":"2019","journal-title":"MBO Molecular Medicine"},{"key":"r89","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1038\/s41467-021-21860-7","article-title":"A Noncanonical AR Addiction Drives Enzalutamide Resistance in Prostate Cancer","volume":"12","author":"Y He","year":"2021","journal-title":"Nature Communications"},{"key":"r90","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1158\/0008-5472.CAN-23-0285","article-title":"Androgen Receptor Variants Confer Castration Resistance in Prostate Cancer by Counteracting Antiandrogen-Induced Ferroptosis","volume":"83","author":"R Sun","year":"2023","journal-title":"Cancer Research"},{"key":"r91","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1002\/pros.23883","article-title":"A Pilot Study of Prostate-specific Membrane Antigen (PSMA) Dynamics in Men Undergoing Treatment for Advanced Prostate Cancer","volume":"79","author":"CJ Paller","year":"2019","journal-title":"The Prostate"},{"key":"r92","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer","volume":"385","author":"O Sartor","year":"2021","journal-title":"The New England Journal Medicine"},{"key":"r93","doi-asserted-by":"crossref","first-page":"560","DOI":"10.2967\/jnumed.121.262552","article-title":"177Lu-PSMA-617 and Idronoxil in Men with End-Stage Metastatic Castration-Resistant Prostate Cancer (LuPIN): Patient Outcomes and Predictors of Treatment Response in a Phase I\/II Trial","volume":"63","author":"S Pathmanandavel","year":"2022","journal-title":"Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine"},{"key":"r94","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/S1470-2045(23)00451-5","article-title":"Single-dose 177Lu-PSMA-617 Followed by Maintenance Pembrolizumab in Patients with Metastatic Castration-resistant Prostate Cancer: An Open-label, Dose-expansion, Phase 1 Trial","volume":"24","author":"R Aggarwal","year":"2023","journal-title":"The Lancet. Oncology"},{"key":"r95","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1093\/oncolo\/oyac279","article-title":"PSMA-Targeted Radiopharmaceuticals in Prostate Cancer: Current Data and New Trials","volume":"28","author":"B Ramnaraign","year":"2023","journal-title":"The Oncologist"},{"key":"r96","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/COC.0000000000000239","article-title":"CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition","volume":"39","author":"EI Buchbinder","year":"2016","journal-title":"American Journal of Clinical Oncology"},{"key":"r97","doi-asserted-by":"crossref","first-page":"28561","DOI":"10.18632\/oncotarget.25564","article-title":"Ipilimumab Plus Nivolumab and DNA-repair Defects in AR-V7-expressing Metastatic Prostate Cancer","volume":"9","author":"K Boudadi","year":"2018","journal-title":"Oncotarget"},{"key":"r98","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1002\/pros.24110","article-title":"Nivolumab Plus Ipilimumab, With or Without Enzalutamide, in AR-V7-expressing Metastatic Castration-Resistant Prostate Cancer: A Phase-2 Nonrandomized Clinical Trial","volume":"81","author":"E Shenderov","year":"2021","journal-title":"The Prostate"},{"key":"r99","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.ccell.2020.08.007","article-title":"Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant Prostate Cancer: Preliminary Analysis of Patients in the CheckMate 650 Trial","volume":"38","author":"P Sharma","year":"2020","journal-title":"Cancer Cell"},{"key":"r100","doi-asserted-by":"crossref","first-page":"5162","DOI":"10.1158\/1078-0432.CCR-20-0945","article-title":"Multicenter Phase I Trial of a DNA Vaccine Encoding the Androgen Receptor Ligand-binding Domain (pTVG-AR, MVI-118) in Patients with Metastatic Prostate Cancer","volume":"26","author":"CE Kyriakopoulos","year":"2020","journal-title":"Clinical Cancer Research: An Official Journal of the American Association for Cancer Research"},{"key":"r101","first-page":"316","article-title":"Current Understanding of Resistance to Abiraterone and Enzalutamide in Advanced Prostate Cancer","volume":"14","author":"ES Antonarakis","year":"2016","journal-title":"Clinical Advances in Hematology & Oncology"},{"key":"r102","article-title":"Abiraterone or Enzalutamide for Patients With Metastatic Castration-Resistant Prostate Cancer","volume":"7","author":"J La","year":"2024","journal-title":"JAMA Network Open"},{"key":"r103","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1056\/NEJMoa1405095","article-title":"Enzalutamide in Metastatic Prostate Cancer Before Chemotherapy","volume":"371","author":"TM Beer","year":"2014","journal-title":"The New England Journal of Medicine"},{"key":"r104","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S1470-2045(14)71205-7","article-title":"Abiraterone Acetate Plus Prednisone Versus Placebo Plus Prednisone in Chemotherapy-naive Men with Metastatic Castration-resistant Prostate Cancer (COU-AA-302): Final Overall Survival Analysis of a Randomised, Double-blind, Placebo-controlled Phase 3 Study","volume":"16","author":"CJ Ryan","year":"2015","journal-title":"The Lancet. Oncology"},{"key":"r105","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1093\/annonc\/mdx348","article-title":"The Evolution of Chemotherapy for the Treatment of Prostate Cancer","volume":"28","author":"DI Quinn","year":"2017","journal-title":"Annals of Oncology: Official Journal of the European Society for Medical Oncology"},{"key":"r106","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1188\/12.CJON.286-291","article-title":"Managing Side Effects of the Novel Taxane Cabazitaxel in Castrate-resistant Prostate Cancer","volume":"16","author":"S Doyle-Lindrud","year":"2012","journal-title":"Clinical Journal of Oncology Nursing"},{"key":"r107","doi-asserted-by":"crossref","DOI":"10.3390\/molecules28093698","article-title":"PROTACs in the Management of Prostate Cancer","volume":"28","author":"P Yedla","year":"2023","journal-title":"Molecules"},{"key":"r108","doi-asserted-by":"crossref","DOI":"10.1093\/hesc\/9780197583746.001.0001","volume-title":"The Cell: A Molecular Approach","author":"G Cooper","year":"2022"},{"key":"r109","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1038\/s41589-021-00770-1","article-title":"LYTACs That Engage the Asialoglycoprotein Receptor for Targeted Protein Degradation","volume":"17","author":"G Ahn","year":"2021","journal-title":"Nature Chemical Biology"},{"key":"r110","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/s41586-020-2545-9","article-title":"Lysosome-targeting Chimaeras for Degradation of Extracellular Proteins","volume":"584","author":"SM Banik","year":"2020","journal-title":"Nature"},{"key":"r111","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/s41586-022-05235-6","article-title":"Antibody Targeting of E3 Ubiquitin Ligases for Receptor Degradation","volume":"610","author":"H Marei","year":"2022","journal-title":"Nature"},{"key":"r112","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/s41587-022-01456-2","article-title":"Modular Cytokine Receptor-targeting Chimeras for Targeted Degradation of Cell Surface and Extracellular Proteins","volume":"41","author":"K Pance","year":"2023","journal-title":"Nature Biotechnology"},{"key":"r113","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-07947-3","article-title":"Transferrin Receptor Targeting Chimeras for Membrane Protein Degradation","author":"D Zhang","year":"2024","journal-title":"Nature"},{"key":"r114","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1146\/annurev.biochem.67.1.425","article-title":"The Ubiquitin System","volume":"67","author":"A Hershko","year":"1998","journal-title":"Annual Review of Biochemistry"},{"key":"r115","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1146\/annurev-biochem-060310-170328","article-title":"The Ubiquitin Code","volume":"81","author":"D Komander","year":"2012","journal-title":"Annual Review of Biochemistry"},{"key":"r116","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1126\/science.306.5695.400b","article-title":"Nobel Prizes. Gold Medal from Cellular Trash","volume":"306","author":"G Vogel","year":"2004","journal-title":"Science"},{"key":"r117","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.molcel.2004.08.008","article-title":"TAB2 and TAB3 Activate the NF-kappaB Pathway Through Binding to Polyubiquitin Chains","volume":"15","author":"A Kanayama","year":"2004","journal-title":"Molecular Cell"},{"key":"r118","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/s41418-020-00648-0","article-title":"Ubiquitin Signaling in Cell Cycle Control and Tumorigenesis","volume":"28","author":"F Dang","year":"2021","journal-title":"Cell Death & Differentiation"},{"key":"r119","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1146\/annurev-biochem-061516-044916","article-title":"Mechanisms of Deubiquitinase Specificity and Regulation","volume":"86","author":"Mevissen","year":"2017","journal-title":"Annual Review of Biochemistry"},{"key":"r120","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms10239","article-title":"Tripartite Degrons Confer Diversity and Specificity on Regulated Protein Degradation in the Ubiquitin-proteasome System","volume":"7","author":"M Guharoy","year":"2016","journal-title":"Nature Communication"},{"key":"r121","doi-asserted-by":"crossref","first-page":"6704","DOI":"10.1038\/s41467-021-26871-y","article-title":"Genetic Fusions Favor Tumorigenesis Through Degron Loss in Oncogenes","volume":"12","author":"J Liu","year":"2021","journal-title":"Nature Communication"},{"key":"r122","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.semcancer.2020.02.006","article-title":"PROTACs: A Novel Strategy for Cancer Therapy","volume":"67","author":"J Liu","year":"2020","journal-title":"Seminars in Cancer Biology"},{"key":"r123","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1080\/15548627.2020.1718362","article-title":"Targeting Selective Autophagy by AUTAC Degraders","volume":"16","author":"D Takahashi","year":"2020","journal-title":"Autophagy"},{"key":"r124","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.molcel.2019.09.009","article-title":"AUTACs: Cargo-Specific Degraders Using Selective Autophagy","volume":"76","author":"D Takahashi","year":"2019","journal-title":"Molecular Cell"},{"key":"r125","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41586-019-1722-1","article-title":"Allele-selective lowering of mutant HTT protein by HTT-LC3 linker compounds","volume":"575","author":"Z Li","year":"2019","journal-title":"Nature"},{"key":"r126","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1080\/15548627.2019.1688556","article-title":"ATTEC: A Potential New Approach to Target Proteinopathies","volume":"16","author":"Z Li","year":"2020","journal-title":"Autophagy"},{"key":"r127","doi-asserted-by":"crossref","first-page":"8554","DOI":"10.1073\/pnas.141230798","article-title":"Protacs: Chimeric Molecules that Target Proteins to the Skp1-Cullin-F Box Complex for Ubiquitination and Degradation","volume":"98","author":"KM Sakamoto","year":"2001","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"r128","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/nchembio.1858","article-title":"Catalytic In Vivo Protein Knockdown by Small-molecule PROTACs","volume":"11","author":"DP Bondeson","year":"2015","journal-title":"Nature Chemical Biology"},{"key":"r129","doi-asserted-by":"crossref","first-page":"5904","DOI":"10.1016\/j.bmcl.2008.07.114","article-title":"Targeted Intracellular Protein Degradation Induced by a Small Molecule: En Route to Chemical Proteomics","volume":"18","author":"AR Schneekloth","year":"2008","journal-title":"Bioorganic & Medicinal Chemistry Letters"},{"key":"r130","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1126\/science.aab1433","article-title":"DRUG DEVELOPMENT. Phthalimide Conjugation as a Strategy for In Vivo Target Protein Degradation","volume":"348","author":"GE Winter","year":"2015","journal-title":"Science"},{"key":"r131","doi-asserted-by":"crossref","first-page":"8961","DOI":"10.1074\/jbc.M709525200","article-title":"Small Molecules Destabilize cIAP1 by Activating Auto-ubiquitylation","volume":"283","author":"K Sekine","year":"2008","journal-title":"The Journal of Biological Chemistry"},{"key":"r132","article-title":"Discovery of E3 Ligase Ligands for Target Protein Degradation","volume":"27","author":"J Lee","year":"2022","journal-title":"Molecules"},{"key":"r133","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2021.707317","article-title":"E3 Ligase Ligands in Successful PROTACs: An Overview of Syntheses and Linker Attachment Points","volume":"9","author":"A Bricelj","year":"2021","journal-title":"Frontiers in Chemistry"},{"key":"r134","doi-asserted-by":"crossref","first-page":"D1381","DOI":"10.1093\/nar\/gkaa807","article-title":"PROTAC-DB: An Online Database of PROTACs","volume":"49","author":"G Weng","year":"2021","journal-title":"Nucleic Acids Research"},{"key":"r135","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1002\/med.21877","article-title":"Strategies for Designing Proteolysis Targeting Chimaeras (PROTACs)","volume":"42","author":"S He","year":"2022","journal-title":"Medicinal Research Reviews"},{"key":"r136","doi-asserted-by":"crossref","first-page":"273","DOI":"10.37349\/etat.2020.00018","article-title":"Current Strategies for the Design of PROTAC Linkers: A Critical Review","volume":"1","author":"RI Troup","year":"2020","journal-title":"Exploration of Targeted Anti-tumor Therapy"},{"key":"r137","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1021\/acs.jmedchem.8b01631","article-title":"Discovery of ARD-69 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor (AR) for the Treatment of Prostate Cancer","volume":"62","author":"X Han","year":"2019","journal-title":"Journal of Medicinal Chemistry"},{"key":"r138","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1002\/cmdc.200700059","article-title":"Predicting and Tuning Physicochemical Properties in Lead Optimization: Amine Basicities","volume":"2","author":"M Morgenthaler","year":"2007","journal-title":"ChemMedChem"},{"key":"r139","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1021\/jo011051x","article-title":"Substituent Effects on the Acidity of Weak Acids. 1. Bicyclo[2.2.2]octane-1-carboxylic Acids and bicyclo[1.1.1]pentane-1-carboxylic Acids","volume":"67","author":"KB Wiberg","year":"2002","journal-title":"Journal of Organic Chemistry"},{"key":"r140","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.sbi.2020.10.010","article-title":"Mechanisms of Substrate Recognition by the 26S Proteasome","volume":"67","author":"C Davis","year":"2021","journal-title":"Current Opinion in Structural Biology"},{"key":"r141","article-title":"The Evolution of Therapies Targeting Bruton Tyrosine Kinase for the Treatment of Chronic Lymphocytic Leukaemia: Future Perspectives","volume":"15","author":"TA Eyre","year":"2023","journal-title":"Cancers (Basel)"},{"key":"r142","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1038\/s41591-023-02635-7","article-title":"IRAK4 Degrader in Hidradenitis Suppurativa and Atopic Dermatitis: A Phase 1 Trial","volume":"29","author":"L Ackerman","year":"2023","journal-title":"Nature Medicine"},{"key":"r143","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1182\/blood-2018-07-862953","article-title":"Bruton Tyrosine Kinase Degradation as a Therapeutic Strategy for Cancer","volume":"133","author":"D Dobrovolsky","year":"2019","journal-title":"Blood"},{"key":"r144","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41573-020-0082-8","article-title":"Kinase Inhibition in Autoimmunity and Inflammation","volume":"20","author":"AA Zarrin","year":"2021","journal-title":"Nature Reviews. Drug Discovery"},{"key":"r145","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/s41589-020-00686-2","article-title":"Snapshots and Ensembles of BTK and cIAP1 Protein Degrader Ternary Complexes","volume":"17","author":"J Schiemer","year":"2021","journal-title":"Natue Chemical Biology"},{"key":"r146","first-page":"E7285","article-title":"Delineating the Role of Cooperativity in the Design of Potent PROTACs for BTK","volume":"115","author":"A Zorba","year":"2018","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"r147","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1021\/acschembio.8b01094","article-title":"PROTAC-Mediated Degradation of Bruton\u2019s Tyrosine Kinase Is Inhibited by Covalent Binding","volume":"14","author":"CP Tinworth","year":"2019","journal-title":"ACS Chemical Biology"},{"key":"r148","doi-asserted-by":"crossref","first-page":"3564","DOI":"10.1021\/acs.biochem.8b00391","article-title":"Targeting the C481S Ibrutinib-Resistance Mutation in Bruton\u2019s Tyrosine Kinase Using PROTAC-Mediated Degradation","volume":"57","author":"AD Buhimschi","year":"2018","journal-title":"Biochemistry"},{"key":"r149","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1038\/s41422-018-0055-1","article-title":"PROTAC-induced BTK Degradation as a Novel Therapy for Mutated BTK C481S Induced Ibrutinib-resistant B-cell Malignancies","volume":"28","author":"Y Sun","year":"2018","journal-title":"Cell Research"},{"key":"r150","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.semcdb.2003.12.015","article-title":"Tau Protein and Neurodegeneration","volume":"15","author":"M Goedert","year":"2004","journal-title":"Seminars in Cell & Developmental Biology"},{"key":"r151","doi-asserted-by":"crossref","DOI":"10.1126\/science.abb8255","article-title":"Tau: Enabler of Diverse Brain Disorders and Target of Rapidly Evolving Therapeutic Strategies","volume":"371","author":"CW Chang","year":"2021","journal-title":"Science"},{"key":"r152","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aag0481","article-title":"Tau Reduction Prevents Neuronal Loss and Reverses Pathological Tau Deposition and Seeding in Mice with Tauopathy","volume":"9","author":"SL DeVos","year":"2017","journal-title":"Science Translational Medicine"},{"key":"r153","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abe1611","article-title":"Persistent Repression of Tau in the Brain Using Engineered Zinc Finger Protein Transcription Factors","volume":"7","author":"S Wegmann","year":"2021","journal-title":"Science Advances"},{"key":"r154","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.ejmech.2018.01.063","article-title":"Discovery of a Keap1-dependent Peptide PROTAC to Knockdown Tau by Ubiquitination-proteasome Degradation Pathway","volume":"146","author":"M Lu","year":"2018","journal-title":"European Journal of Medicinal Chemistry"},{"key":"r155","doi-asserted-by":"crossref","first-page":"5279","DOI":"10.7150\/thno.55680","article-title":"A Novel Small-molecule PROTAC Selectively Promotes Tau Clearance to Improve Cognitive Functions in Alzheimer-like Models","volume":"11","author":"W Wang","year":"2021","journal-title":"Theranostics"},{"key":"r156","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3233\/JAD-130098","article-title":"Early Clinical PET Imaging Results with the Novel PHF-tau Radioligand [F18]-T808","volume":"38","author":"DT Chien","year":"2014","journal-title":"Journal of Alzheimer\u2019s Disease"},{"key":"r157","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.45457","article-title":"Targeted Degradation of Aberrant Tau in Frontotemporal Dementia Patient-derived Neuronal Cell Models","volume":"8","author":"MC Silva","year":"2019","journal-title":"Elife"},{"key":"r158","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1385\/JMN:17:2:225","article-title":"Lewy Body Pathology in Alzheimer\u2019s Disease","volume":"17","author":"PT Kotzbauer","year":"2001","journal-title":"Journal of Molecular Neuroscience"},{"key":"r159","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.chembiol.2020.05.012","article-title":"Specific Knockdown of \u03b1-Synuclein by Peptide-Directed Proteasome Degradation Rescued Its Associated Neurotoxicity","volume":"27","author":"J Qu","year":"2020","journal-title":"Cell Chemical Biology"},{"key":"r160","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/0092-8674(93)90585-E","article-title":"A Novel Gene Containing a Trinucleotide Repeat that is Expanded and Unstable on Huntington\u2019s Disease Chromosomes. The Huntington\u2019s Disease Collaborative Research Group","volume":"72","year":"1993","journal-title":"Cell"},{"key":"r161","article-title":"Strategies to Investigate Ubiquitination in Huntington\u2019s Disease","volume":"8","author":"KA Sap","year":"2020","journal-title":"Frontiers in Chemistry"},{"key":"r162","doi-asserted-by":"crossref","first-page":"11530","DOI":"10.1002\/anie.201706529","article-title":"Discovery of Small Molecules that Induce the Degradation of Huntingtin","volume":"56","author":"S Tomoshige","year":"2017","journal-title":"Angewandte Chemie (International ed. in English)"},{"key":"r163","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.semcancer.2022.03.025","article-title":"RNA-binding Proteins in Regulating mRNA Stability and Translation: Roles and Mechanisms in Cancer","volume":"86","author":"W Li","year":"2022","journal-title":"Seminars in Cancer Biology"},{"key":"r164","article-title":"RNA-Binding Proteins Hold Key Roles in Function, Dysfunction, and Disease","volume":"10","author":"S Kelaini","year":"2021","journal-title":"Biology (Basel)"},{"key":"r165","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrg2538","article-title":"A Census of Human Transcription Factors: Function, Expression and Evolution","volume":"10","author":"JM Vaquerizas","year":"2009","journal-title":"Nature Reviews. Genetics"},{"key":"r166","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bcp.2015.12.006","article-title":"Targeting Transcription Factors by Small Compounds--Current Strategies and Future Implications","volume":"107","author":"J Hagenbuchner","year":"2016","journal-title":"Biochemical Pharmacology"},{"key":"r167","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/s41573-021-00199-0","article-title":"Advances in Targeting \u2018Undruggable\u2019 Transcription Factors with Small Molecules","volume":"20","author":"MJ Henley","year":"2021","journal-title":"Nature Reviews. Drug Discovery"},{"key":"r168","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.chembiol.2021.03.011","article-title":"Targeted Degradation of Transcription Factors by TRAFTACs: TRAnscription Factor TArgeting Chimeras","volume":"28","author":"Samarasinghe","year":"2021","journal-title":"Cell Chemical Biology"},{"key":"r169","doi-asserted-by":"crossref","first-page":"8902","DOI":"10.1021\/jacs.1c03852","article-title":"TF-PROTACs Enable Targeted Degradation of Transcription Factors","volume":"143","author":"J Liu","year":"2021","journal-title":"Journal of the American Chemical Society"},{"key":"r170","article-title":"Destruction of DNA-Binding Proteins by Programmable Oligonucleotide PROTAC (O\u2019PROTAC): Effective Targeting of LEF1 and ERG","volume":"8","author":"J Shao","year":"2021","journal-title":"Advanced Science (Weinheim, Baden-Wurttemberg, Germany)"},{"key":"r171","doi-asserted-by":"crossref","first-page":"12816","DOI":"10.1039\/D1CC05025G","article-title":"G4-PROTAC: Targeted Degradation of a G-quadruplex Binding Protein","volume":"57","author":"KM Patil","year":"2021","journal-title":"Chemical Communications"},{"key":"r172","doi-asserted-by":"crossref","first-page":"10872","DOI":"10.1021\/jacs.3c02783","article-title":"Telomere Targeting Chimera Enables Targeted Destruction of Telomeric Repeat-Binding Factor Proteins","volume":"145","author":"Z Wang","year":"2023","journal-title":"Journal of the American Chemical Society"},{"key":"r173","doi-asserted-by":"crossref","first-page":"9334","DOI":"10.1021\/jacs.3c02619","article-title":"c-Myc-Targeting PROTAC Based on a TNA-DNA Bivalent Binder for Combination Therapy of Triple-Negative Breast Cancer","volume":"145","author":"X Li","year":"2023","journal-title":"Journal of the American Chemical Society"},{"key":"r174","doi-asserted-by":"crossref","first-page":"21871","DOI":"10.1021\/jacs.3c06023","article-title":"Methylated Nucleotide-Based Proteolysis-Targeting Chimera Enables Targeted Degradation of Methyl-CpG-Binding Protein 2","volume":"145","author":"Z Wang","year":"2023","journal-title":"Journal of the American Chemical Society"},{"key":"r175","doi-asserted-by":"crossref","first-page":"7584","DOI":"10.1021\/jacs.3c13646","article-title":"Structurally Specific Z-DNA Proteolysis Targeting Chimera Enables Targeted Degradation of Adenosine Deaminase Acting on RNA 1","volume":"146","author":"Z Wang","year":"2024","journal-title":"Journal of the American Chemical Society"},{"key":"r176","doi-asserted-by":"crossref","first-page":"18370","DOI":"10.1021\/jacs.9b06422","article-title":"Light-Induced Protein Degradation with Photocaged PROTACs","volume":"141","author":"G Xue","year":"2019","journal-title":"Journal of the American Chemical Society"},{"key":"r177","article-title":"Light-induced Control of Protein Destruction by Opto-PROTAC","volume":"6","author":"J Liu","year":"2020","journal-title":"Science Advances"},{"key":"r178","article-title":"Development of Photocontrolled BRD4 PROTACs for Tongue Squamous Cell Carcinoma (TSCC)","volume":"222","author":"Z Li","year":"2021","journal-title":"Europena Journal of Medicinal Chemistry"},{"key":"r179","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1021\/jacs.9b12718","article-title":"Optical Control of Small Molecule-Induced Protein Degradation","volume":"142","author":"Y Naro","year":"2020","journal-title":"Journal of the American Chemical Society"},{"key":"r180","doi-asserted-by":"crossref","first-page":"5532","DOI":"10.1039\/D0CC00523A","article-title":"A Caged E3 Ligase Ligand for PROTAC-mediated Protein Degradation with Light","volume":"56","author":"CS Kounde","year":"2020","journal-title":"Chemical Communications (Cambridge, England)"},{"key":"r181","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1021\/acscentsci.9b00713","article-title":"Reversible Spatiotemporal Control of Induced Protein Degradation by Bistable PhotoPROTACs","volume":"5","author":"P Pfaff","year":"2019","journal-title":"ACS Central Science"},{"key":"r182","doi-asserted-by":"crossref","first-page":"7380","DOI":"10.1021\/jacs.1c00451","article-title":"Cancer Selective Target Degradation by Folate-Caged PROTACs","volume":"143","author":"J Liu","year":"2021","journal-title":"Journal of the American Chemical Society"},{"key":"r183","doi-asserted-by":"crossref","first-page":"12273","DOI":"10.1021\/acs.jmedchem.1c00901","article-title":"Folate-Guided Protein Degradation by Immunomodulatory Imide Drug-Based Molecular Glues and Proteolysis Targeting Chimeras","volume":"64","author":"H Chen","year":"2021","journal-title":"Journal of Medicinal Chemistry"},{"key":"r184","doi-asserted-by":"crossref","first-page":"12852","DOI":"10.1039\/D1CC05715D","article-title":"Development of Hypoxia-activated PROTAC Exerting a More Potent Effect in Tumor Hypoxia than in Normoxia","volume":"57","author":"W Cheng","year":"2021","journal-title":"Chemical Communications"},{"key":"r185","doi-asserted-by":"crossref","first-page":"5057","DOI":"10.1021\/acs.jmedchem.1c02221","article-title":"Rational Design for Nitroreductase (NTR)-Responsive Proteolysis Targeting Chimeras (PROTACs) Selectively Targeting Tumor Tissues","volume":"65","author":"S Shi","year":"2022","journal-title":"Journal of Medicinal Chemistry"},{"key":"r186","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1021\/jacs.2c10177","article-title":"Radiotherapy-Triggered Proteolysis Targeting Chimera Prodrug Activation in Tumors","volume":"145","author":"C Yang","year":"2023","journal-title":"Journal of the American Chemical Society"},{"key":"r187","article-title":"Stimuli-Responsive PROTACs for Controlled Protein Degradation","volume":"62","author":"K An","year":"2023","journal-title":"Angewandte Chemie (International ed. in English)"},{"key":"r188","doi-asserted-by":"crossref","DOI":"10.1002\/ardp.202100467","article-title":"Design, Synthesis, and Characterization of PROTACs Targeting the Androgen Receptor in Prostate and Lung Cancer Models","volume":"355","author":"LM Gockel","year":"2022","journal-title":"Archiv der Pharmazie (Weinheim)"},{"key":"r189","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112769","article-title":"Design and Characterization of Cereblon-mediated Androgen Receptor Proteolysis-targeting Chimeras","volume":"208","author":"AD Takwale","year":"2020","journal-title":"European Journal of Medicinal Chemistry"},{"key":"r190","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2021.116331","article-title":"Designed, Synthesized and Biological Evaluation of Proteolysis Targeting Chimeras (PROTACs) as AR Degraders for Prostate Cancer Treatment","volume":"45","author":"JJ Liang","year":"2021","journal-title":"Bioorganic & Medicinal Chemistry"},{"key":"r191","article-title":"Chemical Degradation of Androgen Receptor (AR) Using Bicalutamide Analog-Thalidomide PROTACs","volume":"26","author":"GY Kim","year":"2021","journal-title":"Molecules"},{"key":"r192","doi-asserted-by":"crossref","first-page":"12831","DOI":"10.1021\/acs.jmedchem.1c00882","article-title":"Strategies Toward Discovery of Potent and Orally Bioavailable Proteolysis Targeting Chimera Degraders of Androgen Receptor for the Treatment of Prostate Cancer","volume":"64","author":"X Han","year":"2021","journal-title":"Journal of Medicinal Chemistry"},{"key":"r193","doi-asserted-by":"crossref","first-page":"13487","DOI":"10.1021\/acs.jmedchem.1c00900","article-title":"Discovery of ARD-2585 as an Exceptionally Potent and Orally Active PROTAC Degrader of Androgen Receptor for the Treatment of Advanced Prostate Cancer","volume":"64","author":"W Xiang","year":"2021","journal-title":"Journal of Medicinal Chemistry"},{"key":"r194","doi-asserted-by":"crossref","first-page":"11218","DOI":"10.1021\/acs.jmedchem.9b01393","article-title":"Discovery of Highly Potent and Efficient PROTAC Degraders of Androgen Receptor (AR) by Employing Weak Binding Affinity VHL E3 Ligase Ligands","volume":"62","author":"X Han","year":"2019","journal-title":"Journal of Medicinal Chemistry"},{"key":"r195","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113307","article-title":"Discovery of A031 as Effective Proteolysis Targeting Chimera (PROTAC) Androgen Receptor (AR) Degrader for the Treatment of Prostate Cancer","volume":"216","author":"L Chen","year":"2021","journal-title":"European Journal of Medicinal Chemistry"},{"key":"r196","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2022.128870","article-title":"Synthesis and Biological Evaluation of Niclosamide PROTACs","volume":"72","author":"E Munoz","year":"2022","journal-title":"Bioorganic & Medicinal Chemistry Letters"},{"key":"r197","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1158\/1535-7163.MCT-20-0417","article-title":"Effects of MTX-23, A Novel PROTAC of Androgen Receptor Splice Variant-7 and Androgen Receptor, on CRPC Resistant to Second-Line Antiandrogen Therapy","volume":"20","author":"GT Lee","year":"2021","journal-title":"Molecular Cancer Therapeutics"},{"key":"r198","doi-asserted-by":"crossref","first-page":"5554","DOI":"10.1073\/pnas.74.12.5554","article-title":"Genetic Dissection of the Control of Normal Differentiation in Myeloid Leukemic Cells","volume":"74","author":"J Lotem","year":"1977","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"r199","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.neo.2019.12.003","article-title":"Androgen Receptor Degraders Overcome Common Resistance Mechanisms Developed During Prostate Cancer Treatment","volume":"22","author":"S Kregel","year":"2020","journal-title":"Neoplasia"},{"key":"r200","doi-asserted-by":"crossref","first-page":"11158","DOI":"10.1021\/acs.jmedchem.3c00585","article-title":"Discovery of BWA-522, a First-in-Class and Orally Bioavailable PROTAC Degrader of the Androgen Receptor Targeting N-Terminal Domain for the Treatment of Prostate Cancer","volume":"66","author":"B Zhang","year":"2023","journal-title":"Journal of Medicinal Chemistry"},{"key":"r201","doi-asserted-by":"crossref","first-page":"8822","DOI":"10.1021\/acs.jmedchem.3c00405","article-title":"Discovery of ARD-2051 as a Potent and Orally Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor for the Treatment of Advanced Prostate Cancer","volume":"66","author":"X Han","year":"2023","journal-title":"Journal of Medicinal Chemistry"},{"key":"r202","doi-asserted-by":"crossref","first-page":"13280","DOI":"10.1021\/acs.jmedchem.3c01264","article-title":"Discovery of ARD-1676 as a Highly Potent and Orally Efficacious AR PROTAC Degrader with a Broad Activity against AR Mutants for the Treatment of AR + Human Prostate Cancer","volume":"66","author":"W Xiang","year":"2023","journal-title":"Journal of Medicinal Chemistry"},{"key":"r203","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/15384047.2022.2125748","article-title":"BRD4 PROTAC Degrader MZ1 Exerts Anticancer Effects in Acute Myeloid Leukemia by Targeting c-Myc and ANP32B Genes","volume":"23","author":"L Ma","year":"2022","journal-title":"Cancer Biology & Therapy"},{"key":"r204","doi-asserted-by":"crossref","first-page":"7124","DOI":"10.1073\/pnas.1521738113","article-title":"PROTAC-induced BET Protein Degradation as a Therapy for Castration-resistant Prostate Cancer","volume":"113","author":"K Raina","year":"2016","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"r205","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/s41586-020-2925-1","article-title":"Small-molecule-induced Polymerization Triggers Degradation of BCL6","volume":"588","author":"M Slabicki","year":"2020","journal-title":"Nature"},{"key":"r206","doi-asserted-by":"crossref","first-page":"17019","DOI":"10.1021\/jacs.8b08008","article-title":"Addressing Kinase-Independent Functions of Fak via PROTAC-Mediated Degradation","volume":"140","author":"PM Cromm","year":"2018","journal-title":"Journal of the American Chemical Society"},{"key":"r207","doi-asserted-by":"crossref","first-page":"6321","DOI":"10.1002\/anie.201901336","article-title":"Development of Dual and Selective Degraders of Cyclin-Dependent Kinases 4 and 6","volume":"58","author":"B Jiang","year":"2019","journal-title":"Angewandte Chemie (International ed. in English)"},{"key":"r208","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/s41392-023-01647-6","article-title":"Bromodomain and Extraterminal (BET) Proteins: Biological Functions, Diseases, and Targeted Therapy","volume":"8","author":"ZQ Wang","year":"2023","journal-title":"Signal Transduction and Targeted Therapy"},{"key":"r209","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1158\/2159-8290.CD-15-0894","article-title":"Targeting CDK4 and CDK6: From Discovery to Therapy","volume":"6","author":"CJ Sherr","year":"2016","journal-title":"Cancer Discovery"},{"key":"r210","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/ng0495-401","article-title":"In Vivo Amplification of the Androgen Receptor Gene and Progression of Human Prostate Cancer","volume":"9","author":"T Visakorpi","year":"1995","journal-title":"Nature Genetics"},{"key":"r211","first-page":"803","article-title":"Survey of Gene Amplifications During Prostate Cancer Progression by High-throughout Fluorescence In Situ Hybridization on Tissue Microarrays","volume":"59","author":"L Bubendorf","year":"1999","journal-title":"Cancer Research"},{"key":"r212","first-page":"3550","article-title":"Amplification and Overexpression of Androgen Receptor Gene in Hormone-refractory Prostate Cancer","volume":"61","author":"MJ Linja","year":"2001","journal-title":"Cancer Research"},{"key":"r213","doi-asserted-by":"crossref","first-page":"64447","DOI":"10.18632\/oncotarget.10901","article-title":"Molecular Mechanisms Underlying Resistance to Androgen Deprivation Therapy in Prostate Cancer","volume":"7","author":"KM Wadosky","year":"2016","journal-title":"Oncotarget"},{"key":"r214","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/nm972","article-title":"Molecular Determinants of Resistance to Antiandrogen Therapy","volume":"10","author":"CD Chen","year":"2004","journal-title":"Nature Medicine"},{"key":"r215","doi-asserted-by":"crossref","first-page":"14833","DOI":"10.3390\/ijms140714833","article-title":"Posttranslational modification of the androgen receptor in prostate cancer","volume":"14","author":"T van der Steen","year":"2013","journal-title":"International Journal of Molecular Sciences"},{"key":"r216","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/nrurol.2014.320","article-title":"Targeting Heat Shock Proteins in Metastatic Castration-resistant Prostate Cancer","volume":"12","author":"AA Azad","year":"2015","journal-title":"Nature Reviews Urology"},{"key":"r217","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1158\/0008-5472.CAN-08-2764","article-title":"Ligand-independent Androgen Receptor Variants Derived from Splicing of Cryptic Exons Signify Hormone-refractory Prostate Cancer","volume":"69","author":"R Hu","year":"2009","journal-title":"Cancer Research"},{"key":"r218","doi-asserted-by":"crossref","first-page":"5469","DOI":"10.1158\/0008-5472.CAN-08-0594","article-title":"Splicing of a Novel Androgen Receptor Exon Generates a Constitutively Active Androgen Receptor that Mediates Prostate Cancer Therapy Resistance","volume":"68","author":"SM Dehm","year":"2008","journal-title":"Cancer Research"},{"key":"r219","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s12672-014-0190-1","article-title":"Androgen Receptor Splice Variants in the Era of Enzalutamide and Abiraterone","volume":"5","author":"M Nakazawa","year":"2014","journal-title":"Hormones & Cancer"},{"key":"r220","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMoa1315815","article-title":"AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer","volume":"371","author":"ES Antonarakis","year":"2014","journal-title":"The New England Journal of Medicine"},{"key":"r221","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy","volume":"367","author":"HI Scher","year":"2012","journal-title":"The New England Journal of Medicine"},{"key":"r222","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and Increased Survival in Metastatic Prostate Cancer","volume":"364","author":"JS de Bono","year":"2011","journal-title":"The New England Journal of Medicine"},{"key":"r223","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa1209096","article-title":"Abiraterone in Metastatic Prostate Cancer Without Previous Chemotherapy","volume":"368","author":"CJ Ryan","year":"2013","journal-title":"The New England Journal of Medicine"}],"container-title":["Acta Materia Medica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/scienceopen.com\/document_file\/deee95ef-7073-4a0a-824b-1c25295836f8\/ScienceOpen\/amm20240075.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/scienceopen.com\/hosted-document?doi=10.15212\/AMM-2024-0075","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,28]],"date-time":"2025-06-28T03:21:16Z","timestamp":1751080876000},"score":1,"resource":{"primary":{"URL":"https:\/\/scienceopen.com\/hosted-document?doi=10.15212\/AMM-2024-0075"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":223,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.15212\/amm-2024-0075","relation":{},"ISSN":["2737-7946"],"issn-type":[{"value":"2737-7946","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]}}}